Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. More Details
Adequate balance sheet with reasonable growth potential.
Share Price & News
How has Mayne Pharma Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -28.5% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned -6.9% over the past year.
Price Volatility Vs. Market
How volatile is Mayne Pharma Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StDo Insiders Own Lots Of Shares In Mayne Pharma Group Limited (ASX:MYX)?
2 weeks ago | Simply Wall StMayne Pharma Group Limited's (ASX:MYX) Intrinsic Value Is Potentially 91% Above Its Share Price
Is Mayne Pharma Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MYX (A$0.32) is trading below our estimate of fair value (A$0.61)
Significantly Below Fair Value: MYX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MYX is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: MYX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYX is good value based on its PB Ratio (0.5x) compared to the AU Pharmaceuticals industry average (3.2x).
How is Mayne Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYX's is expected to become profitable in the next 3 years.
Revenue vs Market: MYX's revenue (11.2% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: MYX's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYX's Return on Equity is forecast to be low in 3 years time (6%).
How has Mayne Pharma Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYX is currently unprofitable.
Growing Profit Margin: MYX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYX is unprofitable, and losses have increased over the past 5 years at a rate of 55.9% per year.
Accelerating Growth: Unable to compare MYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: MYX has a negative Return on Equity (-9.07%), as it is currently unprofitable.
How is Mayne Pharma Group's financial position?
Financial Position Analysis
Short Term Liabilities: MYX's short term assets (A$490.9M) exceed its short term liabilities (A$219.3M).
Long Term Liabilities: MYX's short term assets (A$490.9M) do not cover its long term liabilities (A$563.6M).
Debt to Equity History and Analysis
Debt Level: MYX's debt to equity ratio (37.3%) is considered satisfactory.
Reducing Debt: MYX's debt to equity ratio has increased from 18.8% to 37.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MYX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MYX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.9% per year.
What is Mayne Pharma Group current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MYX is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Richards (56 yo)
Mr. Scott Anthony Richards has been the Chief Executive Officer and Managing Director of Mayne Pharma Group Limited since February 13, 2012. Mr. Richards joined Mayne Pharma in February 2012. He served as ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD2.11M) is above average for companies of similar size in the Australian market ($USD693.56K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
|MD, CEO & Executive Director||8.67yrs||AU$2.96m||1.54% |
|Chief Financial Officer||0.58yr||AU$1.02m||0.47% |
|President of International Operations||3.75yrs||AU$1.01m||0% |
|Vice President of Investor Relations & Communications||4.92yrs||AU$456.63k||0% |
|Executive VP & General Counsel||7.75yrs||AU$767.48k||0% |
|Vice President of Group Human Resources||2.08yrs||no data||no data|
|Executive Vice President of Specialty Brands Division||2yrs||AU$1.29m||0% |
|Executive Vice President of Generics Products Division||1.08yrs||no data||no data|
|Financial Controller||16.25yrs||no data||no data|
|President of Mayne Pharma USA||3.75yrs||AU$1.21m||0% |
|Associate General Counsel & Company Secretary||0.58yr||no data||no data|
|National Sales & Marketing Director||8.42yrs||AU$101.58k||no data|
Experienced Management: MYX's management team is considered experienced (3.8 years average tenure).
|MD, CEO & Executive Director||8.67yrs||AU$2.96m||1.54% |
|Independent Non-Executive Director||13yrs||AU$153.30k||0.13% |
|Independent Chairman||9.75yrs||AU$303.75k||0.62% |
|Independent Non Executive Director||13.67yrs||AU$131.40k||6.29% |
|Independent Non-Executive Director||2.42yrs||AU$213.99k||0.020% |
|Independent Non-Executive Director||6.17yrs||AU$147.83k||no data|
|Independent Non-Executive Director||2.33yrs||AU$205.46k||0.015% |
|Independent Non-Executive Director||4.08yrs||AU$142.35k||0.0061% |
Experienced Board: MYX's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MYX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.
Mayne Pharma Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Mayne Pharma Group Limited
- Ticker: MYX
- Exchange: ASX
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$545.697m
- Shares outstanding: 1.68b
- Website: https://www.maynepharma.com
Number of Employees
- Mayne Pharma Group Limited
- 1538 Main North Road
- Salisbury South
- South Australia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MYX||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 2007|
|HG6||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2007|
|MAYN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2007|
|MYX||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 2007|
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company o ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 10:37|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.